<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083572</url>
  </required_header>
  <id_info>
    <org_study_id>VSL#3</org_study_id>
    <nct_id>NCT05083572</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic (VSL#3) on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers</brief_title>
  <official_title>Effect of Probiotic (VSL#3) on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers - An Exploratory Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changi General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dysbiosis of the gut microbiome has been recognized to underlie the pathogenesis of various&#xD;
      gastrointestinal conditions. Probiotics are known to exert beneficial effects on gut health&#xD;
      and have great potential for use as microbiome interventions for gastrointestinal and&#xD;
      metabolic diseases. While it is widely known that probiotic bacteria favourably alter the&#xD;
      intestinal microflora balance, their other mechanisms of action have not been systematically&#xD;
      characterized. The ability of probiotics to modulate dysbiosis may lead to reduced levels of&#xD;
      endotoxaemia and oxidative stress. In this study, the investigators propose to examine the&#xD;
      effects of 4-week VSL#3 treatment on the gut microbiome and bacterial translocation in&#xD;
      healthy Asian volunteers with and without colonic lavage or antibiotic treatment. The study&#xD;
      will also examine the same outcome parameters 4 weeks upon cessation of the product. The&#xD;
      findings derived from the study will provide valuable insights into the microbiota changes&#xD;
      associated with colonic lavage or antibiotic treatment, and the use of probiotic (VSL#3).&#xD;
      This has important clinical implications in designing treatment strategies in clinical&#xD;
      practice such as the use of VSL#3 as microbiome interventions with antibiotics which are&#xD;
      known to induce Clostridium difficile-associated diarrhoea, as well as in the therapeutic&#xD;
      management of various diseases associated with dysbiosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized controlled, partially-blinded study with four study arms to (i)&#xD;
      examine the effect of VSL#3 on the gut microbiome with and without colonic lavage, (ii) with&#xD;
      and without antibiotic treatment, (iii) compare the gut microbiome after natural recovery and&#xD;
      with VSL#3 treatment following colonic lavage, and (iv) evaluate the efficacy of VSL#3 in&#xD;
      reducing bacterial translocation and oxidative stress.&#xD;
&#xD;
      Screening Visit Procedures (within 28 days of first dosing):&#xD;
&#xD;
        -  Informed consent;&#xD;
&#xD;
        -  Demography, including date of birth, sex, and race/ethnicity;&#xD;
&#xD;
        -  Body weight and height measurement;&#xD;
&#xD;
        -  Determination of eligibility based on inclusion/exclusion criteria;&#xD;
&#xD;
        -  Adverse event/concomitant medication check;&#xD;
&#xD;
        -  Complete medical/drug history;&#xD;
&#xD;
        -  Alcohol/Smoking history;&#xD;
&#xD;
        -  Blood pressure, heart rate and temperature, taken after resting at a sitting position&#xD;
           for at least 5 minutes;&#xD;
&#xD;
        -  Complete physical examination;&#xD;
&#xD;
        -  Laboratory safety tests (liver panel, renal panel and complete blood count) (10 ml&#xD;
           blood);&#xD;
&#xD;
        -  Urine dipstick pregnancy test (for female subjects only).&#xD;
&#xD;
      Day -14 Procedures (for Group D only):&#xD;
&#xD;
      On reporting to CTRU on Day -14, participants will be reminded of study restrictions and&#xD;
      undergo the following assessments:&#xD;
&#xD;
        -  Interim medical/drug history;&#xD;
&#xD;
        -  Adverse event/concomitant medication check;&#xD;
&#xD;
        -  Blood pressure, heart rate and temperature, taken after resting at a sitting position&#xD;
           for at least 5 minutes;&#xD;
&#xD;
        -  Complete physical examination;&#xD;
&#xD;
        -  Provision of baseline stool sample ~3g (before dosing with rifaximin) (for microbiome&#xD;
           and SCFA);&#xD;
&#xD;
        -  Provision of baseline blood sample ~12ml for flow cytometry and SCFA analysis (before&#xD;
           dosing with rifaximin);&#xD;
&#xD;
        -  Rifaximin on-site dosing;&#xD;
&#xD;
        -  Rifaximin dispensing for home consumption (1 tablet 200mg daily till Day -7).&#xD;
&#xD;
      Day -7 Procedures (for Group D only):&#xD;
&#xD;
      On reporting to CTRU on Day -7, participants will be reminded of study restrictions and&#xD;
      undergo the following assessments:&#xD;
&#xD;
        -  Interim medical/drug history;&#xD;
&#xD;
        -  Adverse event/concomitant medication check;&#xD;
&#xD;
        -  Blood pressure, heart rate and temperature, taken after resting at a sitting position&#xD;
           for at least 5 minutes;&#xD;
&#xD;
        -  Brief physical examination;&#xD;
&#xD;
        -  Provision of stool sample ~3g (for microbiome and SCFA);&#xD;
&#xD;
        -  Provision of blood sample ~12ml for flow cytometry and SCFA analysis;&#xD;
&#xD;
        -  Rifaximin home dosing (1 tablet 200mg in morning);&#xD;
&#xD;
        -  Return of rifaximin for accountability check;&#xD;
&#xD;
        -  Rifaximin dispensing for home consumption (1 tablet 200mg daily till Day 1).&#xD;
&#xD;
      Day -1 Procedures (for Groups A &amp; B only):&#xD;
&#xD;
      On reporting to CTRU on Day -1, participants will be reminded of study restrictions and&#xD;
      undergo the following assessments:&#xD;
&#xD;
        -  Interim medical/drug history;&#xD;
&#xD;
        -  Adverse event/concomitant medication check;&#xD;
&#xD;
        -  Blood pressure, heart rate and temperature, taken after resting at a sitting position&#xD;
           for at least 5 minutes;&#xD;
&#xD;
        -  Complete physical examination;&#xD;
&#xD;
        -  Provision of baseline stool sample ~3g (before dosing with PEG) (for microbiome and&#xD;
           SCFA);&#xD;
&#xD;
        -  Provision of baseline blood sample ~12ml for flow cytometry and SCFA analysis (before&#xD;
           dosing with PEG);&#xD;
&#xD;
        -  PEG dispensing for colonic lavage (home consumption- 2L at 6pm);&#xD;
&#xD;
        -  Telephone call at night for bowel movement and AE check.&#xD;
&#xD;
      Day 1 Procedures:&#xD;
&#xD;
      â€¢ Home consumption of 2L PEG at 6am for colonic lavage.&#xD;
&#xD;
      On reporting to CTRU on Day 1, participants will be reminded of study restrictions and&#xD;
      undergo the following assessments:&#xD;
&#xD;
        -  Interim medical/drug history (for Group C only);&#xD;
&#xD;
        -  Adverse event/concomitant medication check;&#xD;
&#xD;
        -  Blood pressure, heart rate and temperature, taken after resting at a sitting position&#xD;
           for at least 5 minutes (for Group C only);&#xD;
&#xD;
        -  Complete physical examination;&#xD;
&#xD;
        -  Verbal stool symptom assessment (for Group D only);&#xD;
&#xD;
        -  Laboratory safety tests (liver panel, renal panel and complete blood count) (10 ml&#xD;
           blood) (for Group D only);&#xD;
&#xD;
        -  Biomarker test (5 ml blood before dosing) (for Group C only);&#xD;
&#xD;
        -  Endotoxaemia test (5 ml blood 2hrs post-meal) (for Group C only);&#xD;
&#xD;
        -  Provision of stool sample ~3g (before dosing with VSL#3 or Placebo) (for microbiome and&#xD;
           SCFA);&#xD;
&#xD;
        -  Provision of blood sample ~12ml for flow cytometry and SCFA analysis (before dosing with&#xD;
           VSL#3 or Placebo);&#xD;
&#xD;
        -  VSL#3 (Groups A, C &amp; D) or Placebo (Group B) on-site dosing;&#xD;
&#xD;
        -  Return of PEG (Groups A &amp; B) or rifaximin (Group D) for accountability check;&#xD;
&#xD;
        -  VSL#3 or Placebo dispensing for home consumption.&#xD;
&#xD;
      Day 2-28 Procedures:&#xD;
&#xD;
        -  Self-administration of 2 capsules of VSL#3 (Groups A, C &amp; D) or Placebo (Group B) twice&#xD;
           daily (morning and evening) till Day 28;&#xD;
&#xD;
        -  Consumption of the study products will be monitored real-time via electronic means on&#xD;
           mobile devices (video call). All morning dosing should be between 8-10am, and all&#xD;
           evening dosing should happen between 6-8pm;&#xD;
&#xD;
        -  Verbal stool symptom assessment on Day 14.&#xD;
&#xD;
      Day 29 Procedures (+ 2 days):&#xD;
&#xD;
      On reporting to CTRU on Day 29, participants will be reminded of study restrictions and&#xD;
      undergo the following assessments:&#xD;
&#xD;
        -  Adverse event/concomitant medication check;&#xD;
&#xD;
        -  Blood pressure, heart rate and temperature, taken after resting at a sitting position&#xD;
           for at least 5 minutes;&#xD;
&#xD;
        -  Verbal stool symptom assessment;&#xD;
&#xD;
        -  Complete physical examination;&#xD;
&#xD;
        -  Laboratory safety tests (liver panel, renal panel and complete blood count) (10 ml&#xD;
           blood);&#xD;
&#xD;
        -  Biomarker and endotoxaemia tests (10 ml blood) (for Group C only);&#xD;
&#xD;
        -  Provision of stool sample ~3g (for microbiome and SCFA);&#xD;
&#xD;
        -  Provision of blood sample ~12ml for flow cytometry and SCFA analysis;&#xD;
&#xD;
        -  VSL#3 (Groups A, C &amp; D) or Placebo (Group B) home dosing (2 capsules in morning and&#xD;
           evening);&#xD;
&#xD;
        -  Return of VSL#3 (Groups A, C &amp; D) or Placebo (Group B) for accountability check.&#xD;
&#xD;
      Day 56 Procedures (Â± 3 days) (Final Visit):&#xD;
&#xD;
        -  Adverse event/concomitant medication check;&#xD;
&#xD;
        -  Brief physical examination;&#xD;
&#xD;
        -  Verbal stool symptom assessment;&#xD;
&#xD;
        -  Provision of stool sample ~3g (for microbiome and SCFA);&#xD;
&#xD;
        -  Provision of blood sample ~12ml for flow cytometry and SCFA analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>This will be a randomized controlled, partially-blinded study with four study arms to (i) examine the effect of VSL#3 on the gut microbiome with and without colonic lavage, (ii) with and without antibiotic treatment, (iii) compare the gut microbiome after natural recovery and with VSL#3 treatment following colonic lavage, and (iv) evaluate the efficacy of VSL#3 in reducing bacterial translocation and oxidative stress. The subjects will not be informed of the identity of the study product (VSL#3 or placebo) given. However, it is not possible to blind the subjects of the colonic lavage and rifaximin interventions. The investigators and outcomes assessors involved in the data analysis will be blinded to the study group allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome profile using 16S rRNA sequencing</measure>
    <time_frame>2 to 2.5 months</time_frame>
    <description>Fresh stool samples will be collected for microbial DNA extraction at Days -14 and -7 (Group D), Day -1 (Groups A &amp; B), Days 1, 29 and 56 (All groups). Microbial DNA will be extracted from the stool samples and used for 16S rRNA sequencing. Bacterial species present in VSL#3 will be specifically examined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory cytokines using ELISA tests</measure>
    <time_frame>2 to 2.5 months</time_frame>
    <description>Inflammatory cytokines indicative of oxidative damage will be assayed using commercially available Elisa kits on serum samples obtained at Baseline and Day 29 (For Group C only).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial translocation using endotoxin assay</measure>
    <time_frame>2 to 2.5 months</time_frame>
    <description>Blood will be collected 2 hours post meal at baseline and Day 29 for endotoxin LAL assay using commercial kit (For Group C only).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood lymphocyte phenotyping using flow cytometry</measure>
    <time_frame>2 to 2.5 months</time_frame>
    <description>Blood will be collected at specified timepoints for peripheral blood lymphocyte phenotyping by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short chain fatty acids using mass spectrometry</measure>
    <time_frame>2 to 2.5 months</time_frame>
    <description>Stool and blood will be collected at specified timepoints for short chain fatty acid analysis by gas chromatography-mass spectrometry</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Dysbiosis</condition>
  <arm_group>
    <arm_group_label>Group A (Lavage and VSL#3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colonic lavage, followed by VSL#3 treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Lavage and Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colonic lavage, followed by Placebo treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (VSL#3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No colonic lavage, only VSL#3 treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D (Rifaximin and VSL#3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin, followed by VSL#3 treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colonic lavage with polyethylene glycol</intervention_name>
    <description>The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).</description>
    <arm_group_label>Group A (Lavage and VSL#3)</arm_group_label>
    <arm_group_label>Group B (Lavage and Placebo)</arm_group_label>
    <other_name>PEG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>The subjects will self-administer orally two capsules of VSL#3 with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.</description>
    <arm_group_label>Group A (Lavage and VSL#3)</arm_group_label>
    <arm_group_label>Group C (VSL#3)</arm_group_label>
    <arm_group_label>Group D (Rifaximin and VSL#3)</arm_group_label>
    <other_name>VSL#3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic</intervention_name>
    <description>The subjects will undergo pre-treatment to &quot;cleanse&quot; the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of VSL#3 course.</description>
    <arm_group_label>Group D (Rifaximin and VSL#3)</arm_group_label>
    <other_name>Rifaximin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed written informed consent,&#xD;
&#xD;
          2. Aged between 21-65 years of age,&#xD;
&#xD;
          3. Chinese, Malay or Indian ancestry through three generations,&#xD;
&#xD;
          4. Body Weight â‰¥ 50kg, Body Mass Index (BMI) of 18.5 to 29.9 kg/m2, inclusive,&#xD;
&#xD;
          5. Clinical laboratory assessment results within normal limits, unless the deviation is&#xD;
             considered not clinically significant by the investigator,&#xD;
&#xD;
          6. Regular stool every 1-2 days,&#xD;
&#xD;
          7. Satisfactory medical assessment as assessed by physical examination, medical history,&#xD;
             and normal laboratory values or minor variations that are not clinically significant,&#xD;
&#xD;
          8. Ability to communicate with the investigator and to understand and comply with all&#xD;
             requirements of study participation.&#xD;
&#xD;
          9. Both male and female participants (with child-bearing potential) and their partners&#xD;
             have to practise contraception throughout the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any acute illness within 14 days of first dosing, unless otherwise approved by the PI,&#xD;
&#xD;
          2. History or evidence of clinically significant hepatic, renal, cardiovascular,&#xD;
             respiratory, gastrointestinal, immunosuppressive or metabolic disorders, any cancer&#xD;
             types,&#xD;
&#xD;
          3. Declare themselves positive for HIV or viral hepatitis (Hepatitis A, B, C),&#xD;
&#xD;
          4. Treatment within the previous 3 months with antibiotics (subjects are to inform study&#xD;
             staff should they be prescribed antibiotics during the course of the study)&#xD;
&#xD;
          5. Treatment with any prescription or over-the-counter medications, complementary health&#xD;
             products, or herbal supplements within 28 days of first dosing,&#xD;
&#xD;
          6. Consumption of probiotics or lactobacillus-containing products e.g. Yakult, Vitagen or&#xD;
             Yogurt within 4 weeks of first dosing unless approved by the PI,&#xD;
&#xD;
          7. Abnormal biochemistry indicators, unless certified as not clinically significant,&#xD;
&#xD;
          8. Poor peripheral venous access,&#xD;
&#xD;
          9. Irregular bowel habits or complains of constipation problem,&#xD;
&#xD;
         10. Pregnancy or lactation,&#xD;
&#xD;
         11. Known allergic reactions to rifaximin, PEG or VSL#3,&#xD;
&#xD;
         12. History of drug/alcohol abuse,&#xD;
&#xD;
         13. Involvement in the planning or conduct of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiing Leong Ang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changi General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seok Hwee Koo, PhD</last_name>
    <phone>+6568504929</phone>
    <email>seok_hwee_koo@cgh.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siok Luan Ong</last_name>
    </contact>
    <investigator>
      <last_name>Seok Hwee Koo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edmund Jon Deoon Lee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugene Yu Jun Wong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>May Gloriba Manejero Fria</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chin Kimg Tan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Jalanka J, Salonen A, SalojÃ¤rvi J, Ritari J, Immonen O, Marciani L, Gowland P, Hoad C, Garsed K, Lam C, Palva A, Spiller RC, de Vos WM. Effects of bowel cleansing on the intestinal microbiota. Gut. 2015 Oct;64(10):1562-8. doi: 10.1136/gutjnl-2014-307240. Epub 2014 Dec 19.</citation>
    <PMID>25527456</PMID>
  </reference>
  <reference>
    <citation>Valentini L, Pinto A, Bourdel-Marchasson I, Ostan R, Brigidi P, Turroni S, Hrelia S, Hrelia P, Bereswill S, Fischer A, Leoncini E, Malaguti M, Blanc-Bisson C, Durrieu J, Spazzafumo L, Buccolini F, Pryen F, Donini LM, Franceschi C, Lochs H. Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota - The &quot;RISTOMED project&quot;: Randomized controlled trial in healthy older people. Clin Nutr. 2015 Aug;34(4):593-602. doi: 10.1016/j.clnu.2014.09.023. Epub 2014 Oct 8.</citation>
    <PMID>25453395</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 3, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changi General Hospital</investigator_affiliation>
    <investigator_full_name>Tiing Leong Ang</investigator_full_name>
    <investigator_title>Chief and Senior Consultant, Department of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <keyword>Gut microbiome</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Bacterial translocation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

